WO1994004120A3 - Methode de traitement de defaillances sexuelles chez l'animal et chez l'homme au moyen d'un agonsite de h - Google Patents

Methode de traitement de defaillances sexuelles chez l'animal et chez l'homme au moyen d'un agonsite de h Download PDF

Info

Publication number
WO1994004120A3
WO1994004120A3 PCT/BR1993/000027 BR9300027W WO9404120A3 WO 1994004120 A3 WO1994004120 A3 WO 1994004120A3 BR 9300027 W BR9300027 W BR 9300027W WO 9404120 A3 WO9404120 A3 WO 9404120A3
Authority
WO
WIPO (PCT)
Prior art keywords
pct
agonist
sexual dysfunction
animals
methods
Prior art date
Application number
PCT/BR1993/000027
Other languages
English (en)
Other versions
WO1994004120A2 (fr
Inventor
Roberto Dias Nahoum Cesar
Original Assignee
Roberto Dias Nahoum Cesar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Dias Nahoum Cesar filed Critical Roberto Dias Nahoum Cesar
Priority to CA002142875A priority Critical patent/CA2142875A1/fr
Priority to US08/381,945 priority patent/US5908853A/en
Priority to KR1019950700672A priority patent/KR100331754B1/ko
Priority to EP93918819A priority patent/EP0655914B1/fr
Priority to JP50569694A priority patent/JP2002510277A/ja
Priority to AT93918819T priority patent/ATE233091T1/de
Priority to DE69332713T priority patent/DE69332713D1/de
Priority to AU49371/93A priority patent/AU678996C/en
Publication of WO1994004120A2 publication Critical patent/WO1994004120A2/fr
Publication of WO1994004120A3 publication Critical patent/WO1994004120A3/fr
Priority to NZ255278A priority patent/NZ255278A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne la nouvelle utilisation de différentes catégories de médicaments, tels que des agonistes de H2 et de H3, en tant qu'agents érectogènes dans le traitement des défaillances sexuelles chez l'homme et chez la femme.
PCT/BR1993/000027 1992-08-21 1993-08-18 Methode de traitement de defaillances sexuelles chez l'animal et chez l'homme au moyen d'un agonsite de h WO1994004120A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002142875A CA2142875A1 (fr) 1992-08-21 1993-08-18 Utilisation des agonistes h2 et h3 pour le traitement de la dysfonction sexuelle
US08/381,945 US5908853A (en) 1992-08-21 1993-08-18 Compositions
KR1019950700672A KR100331754B1 (ko) 1992-08-21 1993-08-18 동물의발기부전또는불감증치료용약제조성물
EP93918819A EP0655914B1 (fr) 1992-08-21 1993-08-18 Utilisation d'agonistes de l'histamine-2 pour le traitment des troubles sexuels
JP50569694A JP2002510277A (ja) 1992-08-21 1993-08-18 新規組成物
AT93918819T ATE233091T1 (de) 1992-08-21 1993-08-18 Verwendung von histamine-2 agonisten zur behandlung sexueller funktionsstörungen
DE69332713T DE69332713D1 (de) 1992-08-21 1993-08-18 Verwendung von Histamine-2 Agonisten zur Behandlung sexueller Funktionsstörungen
AU49371/93A AU678996C (en) 1992-08-21 1993-08-18 Method of treating sexual dysfunction in animals with an H agonist
NZ255278A NZ255278A (en) 1992-08-21 1995-02-15 Treatment of sexual dysfunction using an h2 agonist (heterocyclic substituted n-methyl thioethyl guanidine or aminopropylisothiourea derivatives)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR929203277A BR9203277A (pt) 1992-08-21 1992-08-21 Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
BR920,3277 1992-08-21

Publications (2)

Publication Number Publication Date
WO1994004120A2 WO1994004120A2 (fr) 1994-03-03
WO1994004120A3 true WO1994004120A3 (fr) 1994-05-26

Family

ID=4054796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR1993/000027 WO1994004120A2 (fr) 1992-08-21 1993-08-18 Methode de traitement de defaillances sexuelles chez l'animal et chez l'homme au moyen d'un agonsite de h

Country Status (13)

Country Link
US (1) US5908853A (fr)
EP (1) EP0655914B1 (fr)
JP (1) JP2002510277A (fr)
KR (1) KR100331754B1 (fr)
AT (1) ATE233091T1 (fr)
BR (1) BR9203277A (fr)
CA (1) CA2142875A1 (fr)
DE (1) DE69332713D1 (fr)
NZ (1) NZ255278A (fr)
OA (1) OA10251A (fr)
TW (1) TW418090B (fr)
WO (1) WO1994004120A2 (fr)
ZA (1) ZA936118B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
GB9608408D0 (en) * 1996-04-23 1996-06-26 Adams Michael A Treatment of erectile dysfunction
FR2748658B1 (fr) * 1996-05-15 2000-08-18 Biotec Centre Sa Utilisation de composes du type "alpha-bloquants" notamment le moxisylyte et/ou ses derives pour le traitement de dysfonctionnements erectiles par voie transmucosale balanique
GR1002847B (el) * 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
DE19728103A1 (de) * 1997-07-02 1999-01-07 Winfried Dr Med Heinicke Pharmazeutisches Präparat zur Behandlung erektiler Dysfunktion sowie Injektionshilfe zur Injektion des Präparats
US20020004529A1 (en) * 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
ZA989513B (en) 1997-10-21 1999-04-21 Alcon Lab Inc Compositions containing histamine H2 agonists and methods of use in treating dry eye
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
GB9802078D0 (en) * 1998-01-30 1998-03-25 Futura Medical Limited Preparation for treatment of erectile dysfunction
FR2774593B1 (fr) * 1998-02-12 2000-05-05 Philippe Gorny Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
GR1003199B (el) 1998-08-14 1999-09-01 Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
FR2786699B1 (fr) * 1998-12-02 2002-10-04 Philippe Gorny Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
DE60131644T2 (de) 2000-05-09 2008-10-30 Nitromed, Inc., Lexington Infrarotthermographie und behandlung von sexuellen dysfunktionen
CA2409592A1 (fr) * 2000-05-22 2001-11-29 Illana Gozes Composition pharmaceutique comprenant des peptides associes au vip destinee au traitement de troubles sexuels
WO2002064212A1 (fr) * 2001-02-13 2002-08-22 Cornell Research Foundation, Inc. Procede et compositions visant a reduire des dysfonctionnements cardiaques a l'aide d'un agoniste de recepteur h3 d'histamine selectif
US20030195186A1 (en) * 2002-04-10 2003-10-16 University Of Florida Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US7622844B1 (en) * 2003-12-30 2009-11-24 Hipercon, Llc Metal fiber brush interface conditioning
US20060013769A1 (en) * 2004-07-16 2006-01-19 Stephen Carter Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
US20090197892A1 (en) * 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness
US9034389B2 (en) * 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US20140121256A1 (en) * 2012-10-26 2014-05-01 Beech Tree Labs, Inc. Method of treating muscular weakness comprising administering a composition comprising an effective amount of histamine and/or serotonin
CA3050082A1 (fr) 2016-04-04 2017-10-12 Omeza LLC Composition topique d'huile de poisson

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293562A (en) * 1979-07-02 1981-10-06 Arnold Ritter Methods of obtaining anorexic effects using a combination of amphetamines and cimetidine
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013659A (en) * 1973-07-13 1977-03-22 Smith Kline & French Laboratories Limited Certain n,n'-disubstituted guanidine compounds and their use
ZA771408B (en) * 1976-03-29 1978-04-26 Smith Kline French Lab Pharmaceutical compositions
JPS52156913A (en) * 1976-06-21 1977-12-27 Toko Yakuhin Kogyo Kk Production of injectionable medicine
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
DE3413371C1 (de) * 1984-04-09 1986-01-02 Esselte Pendaflex Corp., Garden City, N.Y. Etikett
US4840952A (en) * 1985-11-01 1989-06-20 Bristol-Myers Company Method for treatment of male impotence
US4863911A (en) * 1986-08-04 1989-09-05 University Of Florida Method for treating male sexual dysfunction
EP0266968A3 (fr) * 1986-11-03 1988-08-24 Gérard G. Cohen Onguent gélifié contenant un agent vasodilatateur
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
IT1221826B (it) * 1988-06-08 1990-07-12 Medico Harvey Srl Centro Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US4931445A (en) * 1988-10-06 1990-06-05 Irwin Goldstein Agents for treatment of male impotence
DE3913954A1 (de) * 1989-04-27 1990-10-31 Stief Georg Arzneimittel zur behandlung erektiler dysfunktionen
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
IT1252603B (it) * 1990-04-19 1995-06-19 Giorgio Cavallini 2,4-diamino-6 piperidino pirimidina-3 ossido topico sul glande nel trattamento delle impotenze erettili
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
IT1247678B (it) * 1990-05-31 1994-12-28 Alberto Reale Metodo per la cura dell'impotenza erettiva maschile
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
GB9012469D0 (en) * 1990-06-05 1990-07-25 Glaxo Group Ltd Medicaments
DK0484581T3 (da) * 1990-11-08 1994-10-24 Boehringer Mannheim Gmbh Anvendelse af thromboxan-A2-receptorantagonister til forhindring af degenerative processer i det penile væv
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293562A (en) * 1979-07-02 1981-10-06 Arnold Ritter Methods of obtaining anorexic effects using a combination of amphetamines and cimetidine
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Am. J. Med. Sci., Vol. 286(3), issued Nov/Dec 1983, PIERCE, J.R., "Cimetidine-Associated Depression and Loss of Libido in a Woman", pages 31-34, see entire article. *
Brit. Med. Jl., issued 10 March 1979, PEDENS, N.R. et al., "Male Sexual Dysfunction During Treatment: Cimetidine", pages 559-560, entire article. *
Brit. Med. Journal, Vol. 1, issued 12 May 1979, ADAKHAN et al., "Male Sexual Dysfunction During Treatment with Cimetidine", pages 1282-1283, see entire article. *
CHEM. ABSTRACTS, Vol. 113, No. 7, issued 13 August 1990, DIEL et al., "Sexual Side Effects of Histamini-H Receptor Antagonists. What is Definite?", Abstract 51928+, Med. Khn. (Munich)(1990):85(5):332-339 (German). *
Science, Vol. 218, issued 29 October 1982, ANANDS et al., "Prenatal and Neonatal Exposure to Cimetidine Results in Gonadal and Sexual Dysfunction in Adult Males", pages 493-494, entire article. *
The Lancet, issued 29 April 1989, KASSIANOS, "Impotence and Nizatidine", see Abstract page 963. *

Also Published As

Publication number Publication date
WO1994004120A2 (fr) 1994-03-03
EP0655914B1 (fr) 2003-02-26
OA10251A (en) 1997-10-07
JP2002510277A (ja) 2002-04-02
ZA936118B (en) 1995-04-20
AU678996B2 (en) 1997-06-19
US5908853A (en) 1999-06-01
KR100331754B1 (ko) 2002-10-04
BR9203277A (pt) 1994-03-01
EP0655914A1 (fr) 1995-06-07
AU4937193A (en) 1994-03-15
KR950702823A (ko) 1995-08-23
TW418090B (en) 2001-01-11
NZ255278A (en) 1999-05-28
CA2142875A1 (fr) 1994-03-03
DE69332713D1 (de) 2003-04-03
EP0655914A4 (fr) 1998-04-22
ATE233091T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
WO1994004120A3 (fr) Methode de traitement de defaillances sexuelles chez l&#39;animal et chez l&#39;homme au moyen d&#39;un agonsite de h
PL309596A1 (en) Application of anticonvulsant agents in treating parkinson disease and parkinsonian syndromes
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
PL309348A1 (en) Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries
CA2285203A1 (fr) Compositions contenant de la capsaicine ou des analogues de capsaicine et un anesthesique local
AU609664B1 (en) A method of treating premature ejaculation using sertraline
AU7814498A (en) Multivalent (in ovo) avian vaccine
DE69634269D1 (de) Verfahren zum modulieren der mikrozirkulation
GB9317636D0 (en) Use of dexmedetomidine
CA2262268A1 (fr) Methode pour traiter l&#39;impuissance causee par des lesions a la moelle epiniere
MX9401406A (es) Agentes receptores de adenosina selectivos para intensificar el conocimiento.
Rupniak et al. Anxiolytic-like and antinociceptive effects of MK-801 accompanied by sedation and ataxia in primates
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
ES2157984T3 (es) Utilizacion de 4&#39;-yodo-4&#39;-desoxidoxorrubicina para el tratamiento de la amidoidosis.
AU2002220492A1 (en) Method for inducing onset of the reproductive cycle of female breeding animals
ES2097816T5 (es) Producto y su uso para el tratamiento de estados catabolicos que comprende ifg-1 autentico y cantidades hipocaloricas de nutrientes.
AU1564500A (en) Method for obtaining and using a combination of a purine and a nitrogen monoxidedonor for preventing or treating sexual dysfunction
RU95119067A (ru) Способ стимуляции половой функции крупного рогатого скота
HK1003422A1 (en) A method of treating liver disease and like indications with vasodilating agents
UA23999C2 (uk) Спосіб одержаhhя засобу &#34;біпекс&#34; для лікуваhhя hейрооhкологічhих захворюваhь
MX9708044A (es) Regulador de tension para animales.
GR3027682T3 (en) 4-guanidinobutyramide for improving blood circulation.
RU94025309A (ru) Средство для лечения больных обменно-алиментарной формой ожирения
ECSP951424A (es) Procedimiento para la administracion de azitromicina

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU CA CH DE DK ES GB JP KP KR LU NL NZ PT SE US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU CA CH DE DK ES GB JP KP KR LU NL NZ PT SE US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 255278

Country of ref document: NZ

Ref document number: 08381945

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2142875

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993918819

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993918819

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1993918819

Country of ref document: EP